ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Apr 4, 2017
Can Vertex Pharmaceuticals Dominate the Race to Treat Cystic Fibrosis?
Cystic Fibrosis is a rare disease that afflicts an estimated seventy-five thousand patients worldwide. Vertex Pharmaceuticals is the first to market with a combination treatment to treat a portion of the overall patient population. Will Vertex win the race to bring forth a triple therapy to treat the vast majority of those afflicted?
Nov 16, 2016
Pharma, Biotech and How to Consider Investing In It
The Valuentum analyst team digs deep into recent trends in big pharma and biotech from the lofty pricing of drugs to political and competitive pressures to ETF considerations and beyond. ~10 mins.
Oct 28, 2016
Podcast: Markets In Motion
The Valuentum analyst team covers market moving information that is top of mind from consumer staples valuations, the political election cycle, utility valuations, energy resource pricing, biotech considerations, Brexit uncertainty and beyond. ~8 minutes.
Jul 26, 2016
Nelson’s Warning to the Board Rooms of America
Image Source: Robert Lyle Bolton. “In some ways, a cash dividend is like paying shareholders with their own money, and making a big deal about it!” – Brian Nelson, CFA
Feb 4, 2015
Yum! Brands’ Fourth-Quarter Earnings Preview
Yum! Brands reports after the bell today. Watch Valuentum’s President Brian Nelson on CNBCAsia at 5:40CT.
Jun 22, 2014
Valuentum Economic Castle™ Rating Update
Members should expect the initial Economic Castle™ ratings.
Jun 9, 2013
Valuentum’s Comprehensive Outlook for Crude Oil and Natural Gas Prices
Let’s take a deep dive into the energy sector. The best dividend growth ideas, the most likely takeout candidates and more...
Aug 23, 2012
Search Dividend Reports by Company Name: Q to Z
Search dividend reports by company name: Q to Z. As a supplement to our 16-page stock reports, our dividend reports assess the safety of a firm's dividend through our Valuentum Dividend Cushion ratio, the potential growth of a firm's dividend by evaluating its capacity and willingness to increase the dividend, the historical track record of the company's dividend performance, and the overall strength of the dividend by putting all of this analysis together. Each report offers our estimate of the future growth rate of the firm's dividend.
Feb 1, 2012
Valuentum's February Edition of its Dividend Growth Newsletter!
The February edition of our Dividend Growth Newsletter is now available.
Jan 2, 2012
Valuentum's January Edition of its Dividend Growth Newsletter!
The January edition of our Dividend Growth Newsletter is now available.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.